Table 1 Baseline characteristics of study participants according to GPA use.
Total (N = 9,133) | Monotherapy of NSAID (N = 2,668) | NSAID plus GPA (N = 6,465) | P value | |
|---|---|---|---|---|
Age, years | 54.2 ± 14.7 | 55.7 ± 13.6 | 53.7 ± 15 | <0.001 |
Male | 3,145 (34.4) | 915 (34.3) | 2,230 (34.5) | 0.879 |
BMI (kg/m2) | 26.8 ± 4.7 | 27.7 ± 4.6 | 26.4 ± 4.5 | 0.121 |
Creatinine (mg/dl) | 0.7 ± 0.46 | 0.7 ± 0.5 | 0.8 ± 0.4 | <0.001 |
Co-morbidity | ||||
Hypertension | 1,133 (12.4) | 325 (12.2) | 808 (12.5) | 0.456 |
Diabetes mellitus | 273 (3) | 99 (3.7) | 174 (2.7) | 0.011 |
Cerebrovascular disease | 103 (1.1) | 32 (1.2) | 71 (1.1) | 0.759 |
Ischemic heart disease | 246 (2.7) | 64 (2.4) | 182 (2.8) | 0.295 |
Concomitant GPAs | ||||
None | 2,668 (29.2) | 2,668 (100) | 0 | |
PPI | 498 (5.5) | 0 | 498 (7.7) | |
H2RA | 1,654 (18.1) | 0 | 1,654 (25.6) | |
Misoprostol | 85 (0.9) | 0 | 85 (1.3) | |
Rebamipide | 1,509 (16.5) | 0 | 1,509 (23.3) | |
Eupatilin | 2,719 (29.8) | 0 | 2,719 (42.1) | |
